Development and Prospective Validation of a Cell-free DNA-based Model for the Early Detection of Pancreatic Cancer

IF 33.3 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-09-22 DOI:10.1158/2159-8290.cd-25-0323

Xiuchao Wang, Hongwei Wang, Meng Zhang, Huikai Li, Yang Liu, HanFei Huang, Jinlong Pei, Jing Huang, Fenglin Zang, Yanhui Zhang, Xingyun Chen, Song Gao, Tiansuo Zhao, Jian Wang, Weidong Ma, Yuexiang Liang, Shangheng Shi, Shuo Li, Wei Li, Tianxing Zhou, Ying Zhang, Xiaonan Cui, Zhao-Xiang Ye, Yan Sun, Li Peng, Xiao Hu, Zhitao Li, Hao Zhang, Dongqin Zhu, Shuang Chang, Jiangyan Zhang, Ruowei Yang, Hua Bao, Xue Wu, Yang Shao, Jun Yu, Chuntao Gao, Yunfeng Cui, Jihui Hao

{"title":"Development and Prospective Validation of a Cell-free DNA-based Model for the Early Detection of Pancreatic Cancer","authors":"Xiuchao Wang, Hongwei Wang, Meng Zhang, Huikai Li, Yang Liu, HanFei Huang, Jinlong Pei, Jing Huang, Fenglin Zang, Yanhui Zhang, Xingyun Chen, Song Gao, Tiansuo Zhao, Jian Wang, Weidong Ma, Yuexiang Liang, Shangheng Shi, Shuo Li, Wei Li, Tianxing Zhou, Ying Zhang, Xiaonan Cui, Zhao-Xiang Ye, Yan Sun, Li Peng, Xiao Hu, Zhitao Li, Hao Zhang, Dongqin Zhu, Shuang Chang, Jiangyan Zhang, Ruowei Yang, Hua Bao, Xue Wu, Yang Shao, Jun Yu, Chuntao Gao, Yunfeng Cui, Jihui Hao","doi":"10.1158/2159-8290.cd-25-0323","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer (PC) remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a non-invasive circulating cell-free DNA (cfDNA)-based model for early PC detection. In a case-control study comprising 232 PC patients and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC=0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity, established risk factors for PC, further assessed its clinical applicability. The model detected 75% of PC cases, including all Stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, non-invasive tool for early PC detection, warranting further large-scale clinical validation to enhance patient outcomes.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"33 1","pages":""},"PeriodicalIF":33.3000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.cd-25-0323","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic cancer (PC) remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a non-invasive circulating cell-free DNA (cfDNA)-based model for early PC detection. In a case-control study comprising 232 PC patients and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC=0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity, established risk factors for PC, further assessed its clinical applicability. The model detected 75% of PC cases, including all Stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, non-invasive tool for early PC detection, warranting further large-scale clinical validation to enhance patient outcomes.

查看原文本刊更多论文

胰腺癌早期检测无细胞dna模型的建立及前瞻性验证

胰腺癌（PC）仍然是一种高度致命的恶性肿瘤，由于晚期诊断和有限的治疗方案。本研究提出了一种基于非侵入性循环无细胞DNA （cfDNA）的早期PC检测模型的开发和验证。在232例PC患者和235例健康对照的病例对照研究中，该模型显示出较高的诊断准确率（训练时AUC=0.9799，验证时AUC= 0.9622）。一项涉及1926名糖尿病和肥胖症患者的前瞻性队列研究，确定了PC的危险因素，进一步评估了其临床适用性。该模型检测出75%的PC病例，包括所有0期患者，提前期长达298天，显著优于CA19-9。此外，它显示了区分高风险和低风险胰腺囊肿的潜力，从而促进更精确的风险分层。这项研究强调了基于cfdna的筛查作为一种可扩展的、非侵入性的早期PC检测工具的潜力，需要进一步的大规模临床验证来提高患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.